Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity Post author: Post published:December 1, 2023 Post category:uncategorized The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption. You Might Also Like 45 years of progress: Prevention and screening avert millions of cancer deaths December 6, 2024 New advances offer hope for patients with systemic mastocytosis December 9, 2024 Cellular immunotherapy offers hope for solid tumors July 12, 2024